Beyond Deaths per Capita:

Comparative CoViD-19 Mortality Indicators

Updated Version, 7/7/2020

Original Manuscript Submitted 4/29/2020, Published 5/5/2020 at:

https://www.medrxiv.org/content/10.1101/2020.04.29.20085506v1

Patrick Heuveline, Ph.D. and Michael Tzen, M.S.

California Center for Population Research (CCPR)

University of California, Los Angeles (UCLA)

Contact author: Patrick Heuveline <heuveline@soc.ucla.edu>

Acknowledgment

The authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The authors thank Patrick Gerland for clarifications regarding UN demographic data, and Sam Preston and Jason Kerwin for comments on an earlier draft.

Beyond Deaths per Capita:

Comparative CoViD-19 Mortality Indicators

Abstract

The number of CoViD-19 deaths more reliably tracks the progression of the disease across populations than the number of confirmed cases. Substantial age and sex differences in CoViD-19 death rates imply that the number of deaths should be adjusted not just for the total size of the population, but also for its age-and-sex distribution. Following well-established practices in demography, this article discusses several measures based on the number of CoViD-19 deaths over time and across populations. The first measure is an unstandardized occurrence/exposure rate comparable to the Crude Death Rate. To date, the highest value has been in New York, where at its peak it exceeded the state 2017 Crude Death Rate. The second measure is an indirectly standardized rate that can be derived even when the breakdown of CoViD-19 deaths by age and sex required for direct standardization is unavailable. For populations with such breakdowns, we show that direct and indirect standardization yield similar results. Standardization modifies comparison across populations: while New Jersey now has the highest unstandardized rate, Baja California (Mexico) has the highest standardized rate. Finally, extant life tables allow to estimate reductions in life expectancy at birth. In the US, life expectancy is projected to decline this year by more (-.68) than the worst year of the HIV epidemic, or the worst three years of the opioid crisis, and to reach its lowest level since 2008. Substantially larger reductions, exceeding two years, are projected for Ecuador, Chile, New York, New Jersey and Peru.

Beyond Deaths per Capita

Background

As of June $1st$, deaths from the novel coronavirus disease 2019 (CoViD-19) had been reported in 186 of the 235 countries and territories of the United Nations system (UN). As with previous pandemics, $¹$ the disease progression can be more reliably tracked with death than with case</sup> counts. Cumulative CoViD-19 death counts at a given time depend on the determination of the cause of death, delays in reporting deaths to central reporting agencies—different for deaths at home, in hospitals and other institutions—and delays in verification, consolidation and publication at reporting agencies. In the US, for instance, the grim milestone of 100,000 cumulative CoViD-19 deaths was reached at the end of May, when data from the Center for Disease Control and Prevention (CDC) suggested that the number of deaths in the country exceeded expectations based on past trends by about 130,000.² While CoViD-19 deaths might not be fully reported, the death undercount is both easier to estimate and an order-of-magnitude smaller than the proportion of unreported cases. CDC data from large-scale seroprevalence surveys suggest than the number of actual cases might be as much as 10 times the number of confirmed cases³—a situation in no way unique to the US.⁴ CoViD-19 mortality indicators are also more pertinent for assessing public-health measures that were intended less to reduce the eventual number of cases than to "flatten the curve" and eventually limit the number of CoViD-19 deaths by keeping the need for emergency hospitalizations below local hospital capacity.

For comparative purposes, cumulative death counts are affected by several demographic characteristics such as, most obviously, population size. The deaths per capita ratio, however, represent the first rather than the only adjustment that can be taken towards more meaningful CoViD-19 mortality comparisons. Following well-established practices in demography,⁵ this

article presents additional indicators that can be derived with additional demographic data. The corresponding measures are discussed using results for the 186 UN countries and territories with at least one death by June 1st. To illustrate issues of scale, the measures are also calculated at the first sub-national administrative level in China, the US, Brazil, Mexico, Italy and Spain—a total of 362 national and subnational populations.

Methods and Data

We first calculate an occurrence/exposure *rate*, the period Crude CoViD-19 Death Rate (*CCDR*):

$$
CCDR[t_1, t] = \frac{D^{c}[t_1, t]}{N(t_m), (t - t_1)}
$$

where t_1 is an initial time, $D^{C}[t_1,t]$ a cumulative CoViD-19 deaths count between times t_1 and t , and $N(t_m)$ an estimate of the total population size at time t_m between time t_l and time *t*. The difference between this period rate and the deaths per capita ratio is easy to miss when the deaths count in the numerator, identical for both, is an annual number of deaths. In that case, the number of person-years in the denominator of the occurrence/exposure rate can indeed be approximated by population size at some point during the year. However, the two are no longer directly comparable, and the metric of the ratio difficult to interpret, when the deaths counts correspond to periods of different durations. On the contrary, the *CCDR* is expressed in deaths per person-*year* and remains directly comparable to the annual Crude Death Rate (*CDR*) available for most populations. We first calculate the *CCDR* for the period starting on the day of the first death in the population, which was obtained from World Health Organization (WHO) daily situation reports, 6 and ending on June 12. The estimated deaths count on that day was obtained from Johns Hopkins University's Center for Systems Science and Engineering (CSSE)7 and total population size was obtained from the UN. $⁸$ (Additional sources used for sub-national</sup> units are referenced in the Technical Appendix.) Using projections from the University of

Washington's Institute for Health Metrics and Evaluation (IHME),⁹ we also calculate a *CCDR* for the period ending on October 1.

As age and sex variations in CoViD-19 mortality have been clearly established, 10 the period rates should be adjusted to take into account differences in age and sex distributions. Direct age-and-sex standardization requires data on CoViD-19 deaths by age and sex, which are unavailable or unreliable for a majority of UN countries and territories and most sub-national populations. An alternative approach, known as indirect standardization, borrows an age-and-sex pattern of mortality from a well-documented population so that only the age-and-sex distribution of the populations of interest is required. Based on this approach, we calculate the Comparative CoViD-19 Mortality Ratio (*CCMR*):

$$
CCMR[t_1, t] = \frac{D^{C}[t_1, t]}{\sum_{j} \sum_{i}^{US} M_{ij}^{C} N_{ij}(t_m)}
$$

where $^{US}M_{ij}^{C}$ is the CoViD-19 death rate specific to age group *i* and sex *j* in the US and $N_{ij}(t_m)$ is the size of the age group *i* for sex *j* in the population of interest. The reference age-and-sex death rates were obtained from the Centers for Disease Control and Prevention (CDC) weekly-updated distribution of CoViD-19 deaths by age and sex in the US,¹¹ selected because this is to date the largest number of CoViD-19 deaths distributed by age and sex. Unavailable only for the 13 countries/territories whose population size is less than 90,000, population age-and-sex distributions were taken from the UN data and, for subnational populations, national statistics.

Multiplying a population *CCMR* by the US *CCDR* yields an Indirectly age-and-sex Standardized CoViD-19 Death Rate (*ISCDR*) for that population, with the US age-and-sex population distribution as the standard:

$$
ISCDR[t_1, t] = \sum_{j} \sum_{i} {^{US}M_{ij}^c \cdot CCMR[t_1, t] \cdot {^{US}N_{ij}(t_m)}}
$$

CCMR and *ISCDR* are again calculated both for CSSE current estimates and IHME October-1 projections.

Last, life expectancy at birth provides a summary indicator of mortality in a population in a more intuitive metric (years) than these rates. A standard demographic technique allows to estimate the impact that *eliminating* a cause of death would have on life expectancy at birth. When a prior period life table (i.e., not factoring CoViD-19 mortality) is available, applying this technique backward allows to translate a cumulative CoViD-19-deaths forecast for the same period into a CoViD-19-induced *reduction* in male and female life expectancies at birth. Although they pertain to October $1st$, the IHME projections were used as conservative projections of the cumulative number of CoViD-19 deaths in 2020 to derive new male and female life expectancies at birth in 244 populations with extant life tables (153 countries, plus Italian regions, Spanish autonomous communities and US states). Calculations required a previous projection of the male and female year-2020 life tables in these populations. For countries, these were again derived from UN data, by interpolation between the 2015-20 estimates and 2020-25 projections. For sub-national populations, life tables available from national statistical institutes were extrapolated to 2020. Additional details on their calculation are described in the online supplementary materials of this article.

Results

To illustrate the properties of these indicators, we briefly describe results from the July-3 updates of the CCSE, IHME and CDC data. (Full results for that week, ranked on *CCMR* values, are also available in the online supplementary materials of this article). Across countries, Belgium has the highest current-period *CCDR* value (2.78 per thousand), followed by the United Kingdom, Spain, Sweden, Italy, France and the US (1.15 per thousand). Four Italian regions, 4 Spanish

autonomous communities and 6 US states have higher current-period *CCDR* value than Belgium, with the highest *CCDR* currently in New Jersey (5.58 per thousand).

The main motivation for the *CCDR* is not to compare CoViD-19 mortality across populations, however, but rather to compare CoViD-19 and overall mortality. The highest *CCDR* value to date has been reached in New York (9.44 per thousand on 4/25) where it exceeded the state's most recent annual *CDR* (7.83 per thousand in 2017). 12. The period *CCDR* remained above the 2017 *CDR* until May 20 (Figure 1). Ignoring seasonality and period trends in overall mortality, this indicates roughly equivalent mortality from CoViD-19 and from all other causes combined between March 14 (first death) and May 20.

Figure 1: Estimated value of the period *CCDR*, New York (in deaths per 1,000 person-years, period starting on March 14 and ending on day shown on the horizontal axis) Sources: CDC (*CDR*) and authors' calculations (*CCDR*, see technical appendix)

The effects of indirect age-standardization are illustrated in Figure 2, comparing currentperiod *CCDR* and *ISCDR* values for selected national and subnational populations. By construction, the *CCMR* equals 1 and the *CCDR* and *ISCDR* are the same in the US, but the

standardized *ISCDR* is lower than the unstandardized *CCDR* in Europe, whereas the standardized rate can be two to three times the unstandardized rate in Mexico and South American countries. Baja California (Mexico) currently has the highest standardized rate. Several other Mexican (e.g., Mexico City) and Brazilian States (e.g., Ceara, Rio de Janeiro) have standardized rates lower than New Jersey and New York, but higher than Lombardy or Madrid.

Figure 2: Estimated value of the *CCDR* and *ISCDR* (in deaths per 1,000 person-years), by country and subnational unit (countries and subnational units with the largest *ISCDR* values and a population size over 10 million plus subnational units with the largest *ISCDR* in their respective countries) Sources: Authors' calculations (see technical appendix)

As for the future mortality impact, the largest projected reductions in 2020 life expectancies at birth are in South America and the US, exceeding two years in Ecuador, Chile, New York, New Jersey and Peru. Excluding countries still early in the diffusion of the virus and

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.04.29.20085506;](https://doi.org/10.1101/2020.04.29.20085506) this version posted July 11, 2020. The copyright holder for this preprint

for which projections remain unstable (defined as below the current *CCDR* threshold of .5 deaths per thousand person-years), Figure 3 shows reductions exceeding 1.3 years are also projected for Brazil, Mexico, four additional US states, as well as subnational populations in Italy (Lombardy and Aosta Valley) and Spain (Community of Madrid).

Figure 3: Estimated reduction in life expectancy at birth for year 2020, both sexes (in years), by country and subnational unit (countries and subnational units with a current *CCDR* equal or larger than .5 deaths per thousand person-years)

Sources: Authors' calculations (see technical appendix)

Reduction in life expectancy at birth is both an age standardized and an easily interpretable metric. In particular, it allows for comparing the mortality impact of CoViD-19 with prior public health crises that might have interrupted the secular increase in life

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.04.29.20085506;](https://doi.org/10.1101/2020.04.29.20085506) this version posted July 11, 2020. The copyright holder for this preprint

expectancies. While the projected reduction in the US (-.68 years) is much lower than in the populations shown in Figure 3, for instance, CoViD-19 would still reduce life expectancy this year by more than the worst year of the HIV epidemic (from 75.8 years in 1992 to 75.5 years in 1993), or the worst three years of the opioid-overdose crisis (from 78.9 years in 2014 to 78.6 years in 2017).¹³ As illustrated in Figure 4, CoViD-19 is projected to reduce US life expectancy at birth in 2020 to its lowest level since 2008.

Figure 4: Estimated life expectancy at birth, U.S. population, both sexes, by year Sources: CDC (2009-2017), UN and authors' calculations (2017-2020, see technical appendix)

Discussion

The results above illustrate the properties of different comparative indicators of CoViD-19 mortality. For comparisons across populations, the *ISCDR*, and *CCMR* on which it builds, control for 3 important factors that contribute to the cumulative count of CoViD-19 deaths in a population: the length of the period over which these deaths are cumulated, the size of the population, and its age-and-sex composition.

With respect to the first of these three factors, both the unstandardized and standardized rates are period indicators that increase and decrease as waves of the pandemic develop. Contrary to the death per capita ratio, which can only increase over time, the period rates begin to decline when the daily number of additional deaths drops below its average for the period. This property of the period rates accurately reflects for CoViD-19 mortality a temporal dimension that can often be neglected for overall mortality. This also implies, however, that comparing *ISCDR* values across populations at too different durations of exposure to CoViD-19 would not be meaningful. As shown in Figure 1, this is more problematic early in the diffusion of the epidemic.

With respect to the second factor, comparing *ISCDR* values at the national or subnational levels illustrate that dividing for population size does not completely remove the effects of scale. To illustrate this, we estimated standardized rates at the first sub-national administrative level in several countries, selected for both their size and within-country differences in CoViD-19 mortality. This showed that if Belgium, followed by 5 other European countries, still have the highest period *CCDR* values, several sub-national populations in Brazil, Italy, Mexico, Spain and the US with populations over 10 million have higher *CCDR* values than Belgium (with 11.6 million inhabitants).

Disaggregation to smaller administrative units may allow for more meaningful comparisons, but might be impeded by data availability. In this respect, indirect standardization has the advantage of not requiring data on CoViD-19 deaths by age and sex that may not be available or reliable for smaller areas. As a breakdown of CoViD-19 deaths *is* available from a

11

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.04.29.20085506;](https://doi.org/10.1101/2020.04.29.20085506) this version posted July 11, 2020. The copyright holder for this preprint

number of European countries¹⁴ and US states, the *ISCDR* can actually be compared to a Directly age-and-sex Standardized CoViD-19 Death Rate (*DSCDR*) with the US age-and-sex population distribution as the standard. Comparing unstandardized with directly and indirectly standardized rate 7 European countries and 6 states, Figure 5 shows that indirect standardization is a valid alternative to direct standardization.

Figure 5: Estimated value of the *CCDR*, *ISCDR* and *DSCDR* (in deaths per 1,000 person-years), by country and state (countries and subnational units with a population size over 10 million and the largest *ISCDR* values)

Sources: CDC, Ined and authors' calculations (see technical appendix)

Substantial uncertainties remain as regards the direct and indirect mortality impact of the pandemic. The direct impact concerns the number of CoViD-19 deaths, for which the main

factors of uncertainty are (1) the degree to which CoViD-19 deaths have been properly reported as the cause of death and (2) the future diffusion and fatality rate of the virus. With respect to the latter, the CDC currently tracks no less than 15 forecasting models.¹⁵ Our choice of the IHME projections among those to illustrate the properties of the different indicators was not based on a quality assessment, which would be beyond our expertise. The IHME projections have a broader international coverage and longer time horizon that made them more suitable to illustrate the various indicators than other models. Comparisons with other models when populations and horizons overlap do not show the IHME projections as particularly alarmist. Adding that the current projections do not include any "second wave" of CoViD-19 deaths, the cumulative number of CoViD-19 deaths in 2020 appears more likely to be higher than lower than the numbers used here to calculate future rates and life expectancy reductions.

The indirect impact refers to the "downstream" effects of the pandemic and mitigating policies on mortality from other causes. As mentioned above, recent CDC data suggest that the cumulative number of CoViD-19 deaths does not fully account for the overall increase in mortality, which could be due to under-reporting of CoViD-19 as a cause of death or an increase in other-cause mortality. All else equal, 2020 life-expectancy reductions would be underestimated, regardless of whether CoViD-19 deaths are under-reported or mortality from other causes increases, because reductions are estimated on the assumption that mortality from other causes remains unchanged. We cannot rule out, however, a decline of mortality from other causes that would have been hidden initially by under-reporting of CoViD-19 deaths. In this case, the indirect impact would partially compensate the direct mortality impact of CoViD-19.16

To be sure, the rapidly evolving data and understanding of CoViD-19 mortality will likely continue to require frequent updates and flexibility. We update the values of the indicators

13

discussed above weekly from updates of the CCSE, IHME and CDC data and shared them on a Github repository.17 These calculations can easily be customized for different periods, different geographical scales, or to accommodate uncertainty across different sources of estimates and forecast.

Summary

What is already known? The number of CoViD-19 deaths more reliably tracks the progression of the disease across populations than the number of confirmed cases. Substantial age and sex differences in CoViD-19 death rates imply that the number of deaths should be adjusted not just for the total size of the population, but also for its age-and-sex distribution.

What are the new findings? Indirect standardization produces results quite comparable to those resulting from direct standardization without requiring CoViD-19 deaths by age and sex. Applying indirect standardization, Baja California (Mexico) appears to have the highest CoViD-19 death rate. When available, extant life tables allow to measure the CoViD-19-induced reduction in life expectancy at birth, which according to current projections will exceed two years in Ecuador, Chile, New York, New Jersey and Peru. To put these in perspective, the .68 year reduction projected for the US would reduce life expectancy this year by more than the worst year of the HIV epidemic, or the worst three years of the opioid crisis, and down to its lowest level since 2008.

What do the new findings imply? Age-and-sex standardization reveals the emergence of Mexico and several South American countries as the most affected by CoViD-19 mortality. Reductions in 2020 life expectancy in these countries and some US states will be substantial.

References

¹ Brookmeyer R & Gail MH. AIDS epidemiology: a quantitative approach. Oxford, England: Oxford University Press, 1994.

² Centers for Disease Control and Prevention. Commercial Laboratory Seroprevalence Survey Data.

https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Last used June 9, 2020.

 3 Centers for Disease Control and Prevention. Excess deaths associated with COVID-19.

https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html. Last used July 2, 2020.

⁴ Modi C, Boehm V, Ferraro S, et al. How deadly is COVID-19? A rigorous analysis of excess mortality and age-

dependent fatality rates in Italy. https://www.medrxiv.org/content/10.1101/2020.04.15.20067074v3. May 14,

2020.

⁵ Preston SH, Heuveline P & Guillot M. Demography: measuring and modeling population processes. Blackwell: Malden, MA, Oxford, England & Carlton, Australia, 2001.

⁶ World Health Organization. Daily situation reports. https://www.who.int/emergencies/diseases/novel-

coronavirus-2019/situation-reports/. Last used June 2, 2020.

⁷ Dong E, Du H & Gardne L. An interactive web-based dashboard to track COVID-19 in real time. *The Lancet Inf Dis* (forthcoming). https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30120-1/fulltext. February 19, 2000.

⁸ United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019, Online Edition. Rev. https://population.un.org/wpp/Download/Standard/CSV/. Last used June 2, 2020. ⁹ University of Washington, Institute for Health Metrics and Evaluation. COVID-19 projections.

https://covid19.healthdata.org/. Last used June 12,2020.

 10 Centers for Disease Control and Prevention. Provisional COVID-19 death counts by sex, age and state. https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku. Last used June 12, 2020.

 11 Dowd JB, Andriano L, Brazel DM, et al. Demographic science aids in understanding the spread and fatality rates

- of COVID-19. PNAS 2020,117: 9696-8. https://doi.org/10.1073/pnas.2004911117
- ¹² Kochanek KD., Murphy SL, Xu JQ & Arias E. 2019. Deaths: final data for 2017. NVSR 2019,68(9). Hyattsville, MD:
- National Center for Health Statistics.
- ¹³ Arias E, & Xu JQ. United States life tables, 2017. NVSR 2019,68(7). Hyattsville, MD: National Center for Vital

Statistics.

¹⁴ National Institute for Demographic Studies (INED). The demographics of COVID-19 deaths. https://dc-

covid.site.ined.fr/en/. Last used June 9, 2020.

¹⁵ Centers for Disease Control and Prevention. COVID-19 forecasts: Cumulative deaths.

https://www.cdc.gov/coronavirus/2019-ncov/covid-data/forecasting-us.html. Last used June 9, 2020.

16 Guillot M & Khlat M. 2020. Epidémie de Covid-19: quell impact sur l'espérance de vie en France?

https://theconversation.com/epidemie-de-covid-19-quel-impact-sur-lesperance-de-vie-en-france-141484. Last

used July 1, 2020.

¹⁷ https://github.com/statsccpr/ind-cov-mort